Irish medical device maker Medtronic has acquired privately held American firm Stimgenics for an undisclosed amount.

The acquired company developed a novel spinal cord stimulation (SCS) waveform, differential target multiplexed (DTM), used to treat patients with chronic pain.

The therapy is for use alongside Medtronic’s Intellis platform via the modulation of neurons and glial cells.

Intellis platform is powered by proprietary overdrive battery technology, built to overcome limitations with other SCS systems.

It is optimised for an extensive range of energy demands and said to offer effective long-term pain relief for patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medtronic pain therapies business president Marshall Stanton said: “Medtronic is committed to providing clinically proven therapeutic options for millions of patients suffering from chronic pain around the world.

“We believe that DTM therapy will advance the treatment of chronic pain, supported by clinical evidence and preclinical research on a neuronal-glial mechanism of action.

“It’s an exciting, new proprietary SCS waveform that will be available on the Intellis platform, and we are looking forward to seeing the results of the randomised control trial data later this month at NANS.”

Medtronic states that the DTM waveform has been studied in animal models, showing statistically significant reversal of pain behaviours in comparison to either low frequency or high frequency alone.

Additionally, preclinical studies investigating the genome of nerve-injured animals have suggested that the DTM waveform has a more significant impact on the neural-glial interaction than other frequencies alone.

Stimgenics founder and lead investigator Stimgenics Ricardo Vallejo said: “Stimgenics’ research is deeply rooted in clinical science that began with animal work more than a decade ago.

“Our preclinical data demonstrated that the modulation of both neurons and glial cells may return glial cells to their normal state and modify how they interact with neurons, which could normalise biological processes and break the pain cascade.”

The acquisition follows Medtronic’s acquisition of US-based digital health startup Klue.

Previously, the Irish firm acquired Titan Spine, a US-based surface technology company, in June.